StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Ashish Bahety, Profitmart Securities

BUYGlenmark Pharmaceuticals
Glenmark Pharmaceuticals share price target & all analyst calls

byAshish Bahety, Profitmart SecuritiesHorizon: NA (inferred Swing (≤2wk))26 Aug 2026via CNBC Awaaz.

Entry₹2,392.2Inferred
Target₹2,450
Total upside +2.42% (call closed)
Stop loss₹2,360-1.35% risk
Exit₹2,45026 Aug 2026, 10:00 am
Target hit+2.42%0.00%upside left
Follow Ashish Bahety for new calls(34% target hit, 235 closed calls)Get alertsWatch GLENMARK for new buy/sell callsGet alertsSee 2 active Swing calls on GLENMARKSee 142 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 26 Aug 2026
4 supporting0 opposing
Supports the BUY call (4)

5 advisors have active short-term BUY calls on this stock, with 4 issued in the last 14 days

Advisor consensus · adjacent horizon·26 Aug · today

Glenmark Pharmaceuticals Inc., USA has launched a new Calcium Gluconate Injection product in various strengths and vial sizes.

BSE · Company Update·21 Aug · 5d ago

(opens in new tab)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·21 Aug · 5d ago

Glenmark Pharmaceuticals has received approval from the U.S. FDA for its Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray.

BSE · Company Update·20 Aug · 6d ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Ashish Bahety, Profitmart Securities

Every call and its outcome